GB2330533A - Composition for enhanced uptake of polar drugs from mucosal surfaces - Google Patents

Composition for enhanced uptake of polar drugs from mucosal surfaces

Info

Publication number
GB2330533A
GB2330533A GB9900050A GB9900050A GB2330533A GB 2330533 A GB2330533 A GB 2330533A GB 9900050 A GB9900050 A GB 9900050A GB 9900050 A GB9900050 A GB 9900050A GB 2330533 A GB2330533 A GB 2330533A
Authority
GB
United Kingdom
Prior art keywords
composition
mucosal surfaces
enhanced uptake
polar drugs
metabolisable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB9900050A
Other versions
GB2330533B (en
GB9900050D0 (en
Inventor
Lisbeth Illum
Peter James Watts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Services Ltd
Original Assignee
Danbiosyst UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Danbiosyst UK Ltd filed Critical Danbiosyst UK Ltd
Publication of GB9900050D0 publication Critical patent/GB9900050D0/en
Publication of GB2330533A publication Critical patent/GB2330533A/en
Application granted granted Critical
Publication of GB2330533B publication Critical patent/GB2330533B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Botany (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

A composition for administration to a mucosal surface of a mammal comprising a non-metabolisable bile salt analogue and a therapeutic agent. Preferably the non-metabolisable bile salt analogue is a non-naturally occurring conjugate of cholic acid and an amino acid, and in particular cholylsarcosine. Preferably the therapeutic agent is a polar molecule.
GB9900050A 1996-07-06 1997-07-07 Composition for enhanced uptake of polar drugs from mucosal surfaces Expired - Fee Related GB2330533B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9614235.1A GB9614235D0 (en) 1996-07-06 1996-07-06 Composition for enhanced uptake of polar drugs from mucosal surfaces
PCT/GB1997/001852 WO1998001159A2 (en) 1996-07-06 1997-07-07 Composition for enhanced uptake of polar drugs from mucosal surfaces

Publications (3)

Publication Number Publication Date
GB9900050D0 GB9900050D0 (en) 1999-02-24
GB2330533A true GB2330533A (en) 1999-04-28
GB2330533B GB2330533B (en) 2000-10-25

Family

ID=10796483

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB9614235.1A Pending GB9614235D0 (en) 1996-07-06 1996-07-06 Composition for enhanced uptake of polar drugs from mucosal surfaces
GB9900050A Expired - Fee Related GB2330533B (en) 1996-07-06 1997-07-07 Composition for enhanced uptake of polar drugs from mucosal surfaces

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GBGB9614235.1A Pending GB9614235D0 (en) 1996-07-06 1996-07-06 Composition for enhanced uptake of polar drugs from mucosal surfaces

Country Status (8)

Country Link
EP (1) EP0993305A2 (en)
JP (1) JP2000515503A (en)
KR (1) KR20000023583A (en)
AU (1) AU722724B2 (en)
CA (1) CA2257563A1 (en)
GB (2) GB9614235D0 (en)
NO (1) NO985956L (en)
WO (1) WO1998001159A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6572874B1 (en) * 1998-05-15 2003-06-03 Umd, Inc. Vaginal delivery of bisphosphonates
AU2681300A (en) * 1999-02-22 2000-09-14 Elan Corporation, Plc Solid oral dosage form containing an enhancer
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
GB2355009A (en) 1999-07-30 2001-04-11 Univ Glasgow Peptides conjugated to bile acids/salts
US7053076B2 (en) 2001-08-29 2006-05-30 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
KR100564021B1 (en) * 2002-12-11 2006-03-24 주식회사종근당 Oral formulations for poorly absorptive hydrophilic drugs
DE102004027924A1 (en) * 2004-06-09 2005-12-29 Röhm GmbH & Co. KG Pharmaceutical form containing the active ingredient cholylsarcosine
EP2007397B1 (en) 2006-04-07 2013-07-24 Merrion Research III Limited Solid oral dosage form containing an enhancer
TW200950799A (en) 2008-05-07 2009-12-16 Merrion Res Iii Ltd Compositions of GnRH related compounds and processes of preparation
PT3679941T (en) 2009-06-18 2022-11-10 Serenity Pharmaceuticals Llc Safe desmopressin administration
WO2011120033A1 (en) 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
CA2819234A1 (en) 2011-01-07 2012-07-12 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration
WO2016120378A1 (en) 2015-01-29 2016-08-04 Novo Nordisk A/S Tablets comprising glp-1 agonist and enteric coating
CN108201531A (en) * 2016-12-19 2018-06-26 湖南尔康湘药制药有限公司 Segmented intestine targeted starch capsule of highly dissoluble sulbenicillin sodium and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990007923A1 (en) * 1989-01-19 1990-07-26 California Biotechnology Inc. Transmembrane formulations for drug administration
DE4222647A1 (en) * 1991-07-15 1993-01-21 Sandoz Ag PEPTIDE PREPARATIONS
WO1995001183A1 (en) * 1993-06-29 1995-01-12 Ferring B.V. Compositions for nasal administration of desmopressin
WO1997006813A1 (en) * 1995-08-15 1997-02-27 Asahi Kasei Kogyo Kabushiki Kaisha Mucosal preparation containing physiologically active peptide

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990007923A1 (en) * 1989-01-19 1990-07-26 California Biotechnology Inc. Transmembrane formulations for drug administration
DE4222647A1 (en) * 1991-07-15 1993-01-21 Sandoz Ag PEPTIDE PREPARATIONS
WO1995001183A1 (en) * 1993-06-29 1995-01-12 Ferring B.V. Compositions for nasal administration of desmopressin
WO1997006813A1 (en) * 1995-08-15 1997-02-27 Asahi Kasei Kogyo Kabushiki Kaisha Mucosal preparation containing physiologically active peptide

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
Chemical Abstract à 112:42406 & Congr. Int. Technol. Pharm.,1989, 1, 91-98 (NAGAI et al.), *
Chemical Abstract à 95:109081 & Life Sci., 1981, 29(8), 803-809, (ZIV et al.) *
Chemical Abstract à 98:191258 & Biochem. Pharmacol., 1983, 32(5), 773-776 (ZIV et al.) *
Int. J. Pharm., 1991, 74(2-3), 95-103, (UCHIDA et al.) "Influence of Bile....Derivatives". *
J. Controlled Release, 1997, 46(1/02), 17-30 (KRAMER et al.)"Modified Bile.....Peptides and Drugs". *
J. Pharm. Sci., 1987, 76(5), 351-355, (LONGENECKER et al.) "Effects of ....Insulin in Sheep". *
J. Pharm. Sci., 1994, 83(10), 1465-1469, (SCOTT-MONCRIEFF etal.) "Enhancement...Micelles in Dogs". *
J. Pharmacobio-Dyn., 1988, 11(6), 395-401, (NAKADA et al.) "The Effect of Additives....in Rats". *
J. Pharmacobio-Dyn., 1989, 12(12), 736-743, (NAKADA et al.) "The Effect of Bile..Calcitonin in Rats" *
J. Pharmacol. Exp. Ther., 1988, 244(1), 23-28,(AUNGST et al)"Comparison...Absorption Promoter". *
Proc. Natl. Acad. Sci. USA, 1985, 82(21), 7419-7423 (GORDON et al.), "Nasal....Bile Salts". *

Also Published As

Publication number Publication date
WO1998001159A3 (en) 1998-03-26
CA2257563A1 (en) 1998-01-15
WO1998001159A2 (en) 1998-01-15
NO985956D0 (en) 1998-12-18
JP2000515503A (en) 2000-11-21
KR20000023583A (en) 2000-04-25
AU722724B2 (en) 2000-08-10
GB9614235D0 (en) 1996-09-04
EP0993305A2 (en) 2000-04-19
NO985956L (en) 1998-12-18
AU3453997A (en) 1998-02-02
GB2330533B (en) 2000-10-25
GB9900050D0 (en) 1999-02-24

Similar Documents

Publication Publication Date Title
GB2330533A (en) Composition for enhanced uptake of polar drugs from mucosal surfaces
EP0783299A4 (en) Compounds and compositions for delivering active agents
EP2016950A8 (en) Pharmaceutical composition comprising an exendin-4 peptide
NO20001567D0 (en) Bioadhesive compositions and methods for topical administration of active agents
WO1997044063A3 (en) Dha-pharmaceutical agent conjugates
WO2003079972A3 (en) Active agent delivery systems and methods for protecting and administering active agents
IL143661A0 (en) Compositions and methods for amelioration of human female sexual dysfunction
AU6278298A (en) Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
UA65561A (en) Therapeutic agent for lymphatic tumors
CA2140361A1 (en) Composition and methods for decreasing muscle breakdown
BR0008443A (en) Inhibitors of branched-chain amino acid-dependent aminotranspheres and their use in the treatment of diabetic retinopathy
WO2002058589A3 (en) Agents and methods for promoting bone growth
AU2001248307A1 (en) Method for treating kidney disorders
RU99103692A (en) AMINO ACID COMPOSITIONS AND THEIR APPLICATION IN IMMUNO DEPRESSION
NO964561D0 (en) Tri, tetra, penta, and polypeptides, and their use as an antidepressant
DK0773782T3 (en) Terpene derivatives (sarcodictyins) use as antitumor agents
AU2921999A (en) Indole-2,3-dione-3-oxime derivatives for therapeutic use
HUP0203050A2 (en) Treating endometriosis or infertility, or improving fertility
WO1999038506A3 (en) Use of topical preparations of glyceryl trinitrate and lanolin for the treatment of erectile dysfunction
AU3739500A (en) Protease resistant flint analogs
AU3354997A (en) Topical composition containing amino acid in combination with either interferon or thymidine derivatives for treating viral or inflammation diseases
DE69815277D1 (en) NIMELULIDE CONTAINING PHARMACEUTICAL PREPARATION FOR ORAL ADMINISTRATION
WO2001045714A3 (en) Formulations of adenosine a1 agonists
CA2386627A1 (en) Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders
UA33773C2 (en) "reumocain" remedy for preventing and treating pathology of neuromuscular and locomotor systems

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20020707